Author

Joel Petersson 1

1 Abbvie Inc, North Chicago, United States

CHARACTERIZATION OF MUCOSAL HEALING WITH ADALIMUMAB TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE FROM EXTEND

Walter Reinisch, Jean-Frederic Colombel, Geert R. D'Haens, William Sandborn, Paul Rutgeerts, Joel Petersson, Samantha Eichner, Annalisa Iezzi, Roopal B Thakkar

CLINICAL BENEFIT OF ADALIMUMAB DOSE ADJUSTMENT FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE IN EXTEND

Jean-Frederic Colombel, Paul Rutgeerts, William Sandborn, Douglas C. Wolf, Walter Reinisch, Gert Van Assche, Samantha Eichner, Joel Petersson, Anne M. Robinson, Roopal B Thakkar

High versus standard adalimumab induction dosing regimens in patients with moderately to severely active ulcerative colitis: results from the SERENE-UC induction study

Julian Panés, Jean-Frederic Colombel, Geert R. D'Haens, Stefan Schreiber, Remo Panaccione, Laurent Peyrin-Biroulet, Edward Loftus, Jr, Silvio Danese, Edouard Louis, Alessandro Armuzzi, Marc Ferrante, Harald Vogelsang, Jessica Lefebvre, Thao Doan, Nisha V. Kwatra, Nael M. Mostafa, Wangang Xie, Bidan Huang, Joel Petersson;;

MEDICATION ADHERENCE IN INFLAMMATORY BOWEL DISEASE IN THE GLOBAL ALIGN STUDY: IMPACT OF CONCERNS AND PERCEIVED NECESSITY OF IMMUNOSUPPRESSANTS, 5-AMINOSALICYLATES, AND TUMOR NECROSIS FACTOR INHIBITORS

Pierre Michetti, Laurent Peyrin-Biroulet, Edouard Louis, Mark S. Silverberg, John Weinman, Julia Sommer, Joel Petersson, Brandee L Pappalardo, Pascal Nurwakagari, Nicole Selenko-Gebauer

SUPERIOR ENDOSCOPIC AND DEEP REMISSION OUTCOMES IN ADULTS WITH MODERATE TO SEVERE CROHN'S DISEASE MANAGED WITH TREAT TO TARGET APPROACH VERSUS CLINICAL SYMPTOMS: DATA FROM CALM

Jean-Frederic Colombel, Remo Panaccione, Peter Bossuyt, Milan Lukas, Filip Baert, T. Vanásek, Ahmet Danalıoğlu, Gottfried Novacek, Alessandro Armuzzi, Xavier Hebuterne, Simon Travis, Silvio Danese, Walter Reinisch, William Sandborn, Paul Rutgeerts, Daniel W. Hommes, Stefan Schreiber, Ezequiel Neimark, Bidan Huang, Qian Z

DE-ESCALATING THERAPY IN PATIENTS WITH CROHN'S DISEASE RECEIVING ADALIMUMAB: A SUBGROUP ANALYSIS OF THE CALM STUDY

Peter Bossuyt, Geert R. D'Haens, Remo Panaccione, William Sandborn, Walter Reinisch, Simon Travis, Stefan Schreiber, Alessandro Armuzzi, Silvio Danese, Sofie Berg, Joel Petersson, Jen-Fue Maa, Ezequiel Neimark, Jean-Frederic Colombel

PYRAMID REGISTRY: LONG-TERM SAFETY OF ADALIMUMAB BY AGE IN PATIENTS WITH CROHN’S DISEASE

Jean-Frederic Colombel, Geert R. D'Haens, Walter Reinisch, Edward V Loftus Jr, Remo Panaccione, Jack Satsangi, Gabriela Alperovich, Sofie Berg, Jasmina Kalabic, Mareike Bereswill, Joel Petersson, Anne M. Robinson

ADALIMUMAB LONG-TERM EFFECTIVENESS IN ADALIMUMAB-NAIVE PATIENTS WITH CROHN'S DISEASE: FINAL DATA FROM PYRAMID REGISTRY

Edward V Loftus Jr, Geert R. D'Haens, Walter Reinisch, Jack Satsangi, Remo Panaccione, Sofie Berg, Gabriela Alperovich, Mareike Bereswill, Jasmina Kalabic, Martha Skup, Joel Petersson, Anne M. Robinson

A TREAT TO TARGET APPROACH DECREASES THE RATE OF CD-RELATED ADVERSE OUTCOMES VERSUS A CLINICAL APPROACH IN PATIENTS WITH MODERATE TO SEVERELY ACTIVE CROHN'S DISEASE: DATA FROM CALM

Jean-Frederic Colombel, Remo Panaccione, Peter Bossuyt, Filip Baert, T. Vanásek, Ahmet Danalıoğlu, Gottfried Novacek, Alessandro Armuzzi, Xavier Hebuterne, Simon Travis, Silvio Danese, Walter Reinisch, William Sandborn, Paul Rutgeerts, Daniel W. Hommes, Stefan Schreiber, Ezequiel Neimark, Bidan Huang, Qian Zhou, Wan J Le

EFFECT OF ADALIMUMAB ON CLINICAL AND HEALTH-RELATED QUALITY OF LIFE OUTCOMES BY DISEASE SEVERITY AND PRIOR TUMOUR NECROSIS FACTOR INHIBITOR USE IN PATIENTS WITH ULCERATIVE COLITIS IN A CLINICAL PRACTICE SETTING: SUBGROUP ANALYSES FROM INSPIRADA

Simon Travis, Brian G. Feagan, Laurent Peyrin-Biroulet, Remo Panaccione, Silvio Danese, Joel Petersson, Andreas Lazar, Anne M. Robinson, Naijun Chen, Martha Skup, Wan-Ju Lee

Item 1 - 10 / 17
1
2